These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9713502)

  • 1. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance.
    Caffrey PB; Frenkel GD
    Anticancer Res; 1998; 18(4C):3017-20. PubMed ID: 9713502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
    Caffrey PB; Zhang Y; Frenkel GD
    Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of the development of melphalan resistance in vitro by selenite.
    Caffrey PB; Zhu M; Frenkel GD
    Biol Trace Elem Res; 1998 Dec; 65(3):187-95. PubMed ID: 9892492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
    Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
    Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selenite enhances and prolongs the efficacy of cisplatin treatment of human ovarian tumor xenografts.
    Caffrey PB; Frenkel GD
    In Vivo; 2012; 26(4):549-52. PubMed ID: 22773566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of melphalan-resistant tumors to selenite in vivo.
    Caffrey PB; Frenkel GD
    Cancer Lett; 1997 Dec; 121(2):177-80. PubMed ID: 9570356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo.
    Caffrey PB; Frenkel GD
    Cancer Chemother Pharmacol; 2000; 46(1):74-8. PubMed ID: 10912582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
    Song K; Cowan KH; Sinha BK
    Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of cross-resistance between radiation and antineoplastic drugs.
    Ozols RF; Masuda H; Hamilton TC
    NCI Monogr; 1988; (6):159-65. PubMed ID: 3352759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
    Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
    Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
    Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
    Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect.
    Silver DF; Piver MS
    Gynecol Oncol; 1999 May; 73(2):280-4. PubMed ID: 10329047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme.
    Wang W; Liu G; Zheng J
    Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite.
    Caffrey PB; Frenkel GD
    Anticancer Res; 2013 Oct; 33(10):4249-54. PubMed ID: 24122988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease.
    Masazza G; Lucchini V; Tomasoni A; Peccatori F; Lampasona V; Giudici G; Mangioni C; Biondi A; Giavazzi R
    Cancer Res; 1991 Dec; 51(23 Pt 1):6358-62. PubMed ID: 1933898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin.
    Tsuruo T; Hamilton TC; Louie KG; Behrens BC; Young RC; Ozols RF
    Jpn J Cancer Res; 1986 Sep; 77(9):941-5. PubMed ID: 2429947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D; Williams JI; Pietras RJ
    Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
    Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
    In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.